Comparative Pharmacology
Head-to-head clinical analysis: MANNITOL 10 versus OSMITROL 5 IN WATER IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MANNITOL 10 versus OSMITROL 5 IN WATER IN PLASTIC CONTAINER.
MANNITOL 10% vs OSMITROL 5% IN WATER IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Mannitol is an osmotic diuretic that increases urinary output by raising the osmolarity of glomerular filtrate, thereby reducing tubular reabsorption of water and solutes. It also reduces cerebral edema by creating an osmotic gradient across the blood-brain barrier, drawing water from brain tissue into plasma.
Osmotic diuretic that increases plasma osmolality, drawing water from intracellular spaces into extracellular fluid and increasing renal blood flow. It is filtered by glomerulus and not reabsorbed, leading to increased urinary output and reduction of intracranial/intraocular pressure.
0.25-2 g/kg intravenously as a 10% solution over 30-60 minutes, typically 50-100 g every 6-8 hours.
Intravenous infusion. Usual adult dose: 50-100 grams (500-1000 mL of 5% solution) administered over 30-60 minutes. Frequency: every 6-12 hours as needed for cerebral edema or reduction of intraocular pressure.
None Documented
None Documented
Terminal half-life: 1.1–1.6 hours; prolonged to 6–36 hours in renal impairment
The terminal elimination half-life is approximately 1.5 to 2 hours in adults with normal renal function. This can be prolonged to 6-12 hours in patients with renal impairment, requiring dose adjustment.
Renal: 90% as unchanged drug; <10% metabolized in liver to fructose and glucose; fecal: negligible
Mannitol is excreted primarily by the kidneys via glomerular filtration, with approximately 80% of an administered dose appearing unchanged in urine within 3 hours. Less than 10% undergoes tubular reabsorption; negligible biliary or fecal elimination (<1%).
Category A/B
Category C
Osmotic Diuretic
Osmotic Diuretic